IDH1 and IDH2 Results Explained

glioma classification, R132 and R140 variants

What each line of the report means

Specimen: Tumor tissue or blood, as stated
The specimen source and collection date determine what the result can represent.
Biomarker / finding: IDH1 p.R132H
IDH1 R132H IHC detects a common glioma variant but not every IDH1 or IDH2 mutation.
Classification: Pathogenic
Pathogenicity and clinical evidence are separate judgments; both matter.
Quantitative result: VAF: 31%
The number is assay-specific and should not be interpreted without the laboratory method and tumor context.
Clinical interpretation: Cancer-specific review required
A therapy or trial listed by the laboratory is a lead for discussion, not a treatment recommendation.

How this result is interpreted

  • IDH1 R132H IHC detects a common glioma variant but not every IDH1 or IDH2 mutation.
  • Glioma, cholangiocarcinoma and leukemia use IDH results differently.
  • Read the exact gene and codon, then place it in the diagnosis and disease setting.

What this result cannot tell you

  • A negative result applies only to the tested specimen, assay coverage and detection limit.
  • Tumor purity, sample age, treatment timing and biologic heterogeneity can change what is detected.
  • A listed therapy does not establish eligibility by itself; cancer type, stage, prior treatment and current approvals still matter.

Questions to ask your oncologist

  • Was broad sequencing done if IDH1 R132H immunostaining was negative?
  • What is the exact alteration, score or assay interpretation rather than the shortened positive or negative label?
  • Does this result change an approved treatment now, future testing, or only clinical-trial matching?
  • Could the finding be inherited, and do I need confirmatory germline testing or genetic counseling?
  • Should this biomarker be retested on a newer tissue or blood sample if the disease changes?

Frequently asked questions

Does this result automatically determine treatment?

No. It can open or close a treatment pathway, but the decision also depends on the cancer type, stage, prior treatment, other biomarkers, organ function and current approvals.

Can a negative result be wrong?

A technically valid negative result can still miss an alteration when the sample has little tumor, the assay does not cover the relevant alteration type, or blood contains too little tumor DNA. The report's specimen and methods sections matter.

Can someone independently review this result?

Yes. A Clarity Report can assess the exact finding, assay, specimen, co-alterations, treatment setting and current trial relevance, then return the findings in writing.

Sources

Free 15-minute consultation